AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02951897 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CanPatrolTM to detect CTCs
Description: CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E\&M-) CTCs.
Study NCT02317497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive neurosurgery, if needed
Study NCT02317497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive neurosurgery, if needed
Study NCT02286596 — intervention group
Intervention type: DEVICE
Intervention: dextran sulfate adsorption
Description: Lipid apheresis for 3 hours
Study NCT01425918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Enhancement Intervention
Description: The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
Study NCT01425918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
Study NCT01425918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Education
Description: Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
Study NCT01418963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: single and multiple ascending oral doses
Study NCT01418963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single and multiple oral doses
Study NCT04997226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS or tACS over the left DLPFC with adaptive memory game
Description: This intervention is described in arms 1 and 3.
Study NCT01340664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
Study NCT01340664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule taken orally twice daily with a meal for 18 weeks
Study NCT01340664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 150 mg
Description: 1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
Study NCT01340664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
Study NCT01340664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
Study NCT02217813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 20 mg of current commercial formulation
Study NCT02217813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 20 mg of new formulation
Study NCT03138525 — intervention group
Intervention type: OTHER
Intervention: Blood sampling (MS)
Description: Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
Study NCT01974804 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Study NCT04173988 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: alloCART-19
Description: AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg~* For children with body weight > 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells.
Study NCT04173988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study NCT04173988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion
Study NCT01805154 — intervention group
Intervention type: DEVICE
Intervention: CRT Patients
Description: This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
Study NCT04997226 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS or tACS over the left DLPFC with adaptive memory game
Description: This intervention is described in arms 2 and 4.
Study NCT04351048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stepwise Excavation
Description: * stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~* after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall.
Study NCT04351048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Step Excavation
Description: \*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
Study NCT00416702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAB149
Study NCT05027243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral temporomandibular joint arthroscopy
Description: The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
Study NCT05027243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin® (Merz)
Description: For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
Study NCT03893435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
Study NCT03893435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
Study NCT02951897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CanPatrolTM to detect CTCs
Description: CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E\&M-) CTCs.
Study NCT03295604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCTG+EMD
Description: Miller class I-II gingival recession defects were operated with SCTG+EMD
Study NCT03295604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCTG
Description: Miller class I-II gingival recession defects were operated with SCTG only and
Study NCT00442260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Study NCT00442260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study NCT03138525 — intervention group
Intervention type: OTHER
Intervention: Blood sampling (controls)
Description: Blood samples will be collected once at enrollment.
Study NCT03742570 — intervention group
Intervention type: BEHAVIORAL
Intervention: CBBDQ
Description: a questionnaire for childood bladder and bowel dysfunctions
Study NCT02795754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 PIB
Description: GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
Study NCT02795754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 IR1
Description: GSK2838232 will be available as film-coated tablet for oral use
Study NCT04625426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant
Description: Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
Study NCT04625426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conveen EasiCleanse and Conveen Critic Barrier
Description: Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
Study NCT02795754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 IR2
Description: GSK2838232 will be available as film-coated tablet for oral use
Study NCT04625426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cleansing and Conveen Critic Barrier
Description: Hospital's standard care for IAD management
Study NCT02795754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo PIB
Description: Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
Study NCT02795754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
Study NCT01184326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Study NCT01184326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT01615393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: Single oral dose of 400 mg tablets
Study NCT01615393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Vilona]
Description: Single oral dose of a 400 mg capsule
Study NCT01131780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen + Pseudoephedrine Hydrochloride
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Study NCT01131780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Pseudoephedrine Hydrochloride
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Study NCT02343913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAC checklist
Study NCT02171819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU-A/H5N1, 7.5 mcg
Description: Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
Study NCT02171819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU-A/H5N1, 15 mcg
Description: Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
Study NCT02171819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: PBS, pH 7.2 in 0.5 mL single-dose vials.
Study NCT03684941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Period One
Description: LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
Study NCT03465813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaringGuidance After Breast Cancer Diagnosis
Description: CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
Study NCT03849352 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle changes with the support of health technology
Description: Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
Study NCT03390296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Agonist Monoclonal Antibody PF-04518600
Description: Given IV
Study NCT03684941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Period Two
Description: CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
Study NCT01150760 — intervention group
Intervention type: DRUG
Intervention: Alvimopan
Description: At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
Study NCT00953004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fiber drink and fiber bread
Description: fiber drink or fiber bread three times daily
Study NCT04514588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: caffeine consumption
Description: In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
Study NCT02428673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assisted Standing Treatment Program
Study NCT04569799 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lumason
Description: 2.4 mL per lesion
Study NCT00756704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation guideline implementation
Description: 1. a tutorial on brief cessation counseling for ED nurses and physicians~2. use of an ED algorithm that includes recommended tobacco counseling items~3. fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~4. group feedback to ED staff
Study NCT01851863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
Study NCT01851863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixol-Melitracen(psychological and GI) + Omeprazole
Description: Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
Study NCT01851863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixol-Melitracen(psychological) + Omeprazole
Description: Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
Study NCT01851863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixol-Melitracen(without explanation) + Omeprazole
Description: Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
Study NCT02657876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExpressGraft-C9T1 Skin Tissue
Description: ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
Study NCT01864317 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 7-Tesla MRI
Description: High resolution functional and structural imaging of the visual pathway
Study NCT01864317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Tesla MRI
Description: High resolution functional and structural imaging of the visual pathway
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: Measurement of retinal nerve fiber thickness
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Measurement of retinal nerve fiber thickness
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heidelberg Retina Tomography
Description: Measurement of retinal nerve fiber thickness
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomography
Description: Measurement of retinal nerve fiber thickness
Study NCT01822275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy with Temodar.
Description: Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
Study NCT01822275 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation therapy
Study NCT02365870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rotigotine transdermal patch
Description: Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scanning Laser Polarimetry
Description: Measurement of retinal nerve fiber thickness
Study NCT02365870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive a placebo transdermal patch to be worn daily